Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Lucinda J. Billingham"'
A hypothetical example of an updated DTP for Cohorts 4 to 6 in the Viola trial after observing 0/3 DLT at Dose 0, 1/3 DLT at Dose 1 and 0/3 DLT at Dose 1 for Cohorts 1 to 3 respectively (i.e. pathway 5 in Table 2). This table presents all 64 pathways
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d6a311f1fba250c7dbe3ed61b3a83b0
https://doi.org/10.1158/1078-0432.22461983.v1
https://doi.org/10.1158/1078-0432.22461983.v1
Original DTP for Cohorts 1 to 3 (with cohort size of 3) with all 64 pathways without stopping early for excessive toxicity in Viola. The design will always recommend staying at the lowest dose even when high numbers of DLTs are observed at the lowest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::156394ff520ecab5235b2eb74bcd6cc7
https://doi.org/10.1158/1078-0432.22461986
https://doi.org/10.1158/1078-0432.22461986
The ever-increasing pace of development of novel therapies mandates efficient methodologies for assessment of their tolerability and activity. Evidence increasingly support the merits of model-based dose-finding designs in identifying the recommended
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a2208128856dc3c1e06195cb93755bf
https://doi.org/10.1158/1078-0432.c.6524975.v1
https://doi.org/10.1158/1078-0432.c.6524975.v1
DTP-Heatmap of risk of lowest dose being too toxic. This figure presents a heatmap to highlight any case where there is a high chance that the lowest dose is too toxic (greater than 0.3 DLT rate) based on the accumulated data in each pathway for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bed88b1a40b7d53949a3e36532cc351
https://doi.org/10.1158/1078-0432.22461989
https://doi.org/10.1158/1078-0432.22461989
A hypothetical example of an updated DTP for Cohorts 7 to 9 in the Viola trial with the final recommended MTD. This is based on observing DLT outcomes of 0/3 DLT at Dose 0, 1/3 DLT at Dose 1 and 0/3 DLT at Dose 1 for Cohorts 1 to 3 respectively (path
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::598d255369c85839fe17d38eb0557e40
https://doi.org/10.1158/1078-0432.22461980.v1
https://doi.org/10.1158/1078-0432.22461980.v1
Autor:
Evan Yi-Wen, Yu, Duncan, Nekeman, Lucinda J, Billingham, Nicholas D, James, K K, Cheng, Richard T, Bryan, Anke, Wesselius, Maurice P, Zeegers
Publikováno v:
Bju International
BJU Int
BJU Int
Objectives To quantify the health‐related quality of life (HRQoL) of patients with bladder cancer around the time of diagnosis and to test the hypotheses of a two‐factor model for the HRQoL questionnaire QLQ‐C30. Methods From participants in th
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e25164 (2011)
PurposeDespite discrepant results on clinical utility, several trials are already prospectively randomizing non-small cell lung cancer (NSCLC) patients by ERCC1 status. We aimed to characterize the prognostic and predictive effect of ERCC1 by systema
Externí odkaz:
https://doaj.org/article/6d23c15f72c544d1ba6ec3553e94e073
Autor:
Alex A. Adjei, Mjung-Ju Ahn, Chris I. Amos, Alberto Antonicelli, Hisao Asamura, Todd Atwood, Paul Baas, Joan E. Bailey-Wilson, David Ball, Fabrice Barlesi, Jose G. Bazan, José Belderbos, Andrea Bezjak, Lucinda J. Billingham, Paolo Boffetta, Martina Bonifazi, Julie R. Brahmer, Elisabeth Brambilla, Fraser Brims, Alessandro Brunelli, Ayesha Bryant, Nicholas Campbell, Brett W. Carter, Robert Cerfolio, Byoung Chul Cho, William C.S. Cho, Hak Choy, Chia-Yu Chu, Glenda Colburn, Henri Colt, Rafael Rosell Costa, Gail E. Darling, Mellar Davis, Patricia M. de Groot, Harry J. de Koning, Paul De Leyn, Dirk De Ruysscher, Ayşe Nur Demiral, Jules Derks, Frank C. Detterbeck, Siddhartha Devarakonda, Anne-Marie C. Dingemans, Jessica S. Donington, Carolyn M. Dresler, Steven M. Dubinett, Grace K. Dy, Jeremy J. Erasmus, Alysa Fairchild, Dean A. Fennell, Hiran C. Fernando, Pier Luigi Filosso, Raja Flores, Kwun Fong, Jesme Fox, David R. Gandara, Leena Gandhi, Laurie Gaspar, Stefano Gasparini, Adi F. Gazdar, Giuseppe Giaccone, Nicolas Girard, Peter Goldstraw, Elizabeth M. Gore, Glenwood Goss, Ramaswamy Govindan, Alissa K. Greenberg, Dominique Grunenwald, Matthias Guckenberger, Swati Gulati, Raffit Hassan, Christopher Hazzard, Fiona Hegi, Thomas Hensing, Roy Herbst, Fred R. Hirsch, Nanda Horeweg, David M. Jablons, James R. Jett, Andrew Kaufman, Paul Keall, Karen Kelly, Feng-Ming (Spring) Kong, Kaoru Kubota, Ite A. Laird-Offringa, Primo N. Lara, Janessa Laskin, Quynh-Thu Le, Cécile Le Péchoux, Elvira L. Liclican, Yolande Lievens, Chia-Chi (Josh) Lin, Billy W. Loo, Michael Mac Manus, Homer A. Macapinlac, Fergus Macbeth, William J. Mackillop, Christopher Maher, Isa Mambetsariev, Sumithra J. Mandrekar, Aaron S. Mansfield, Lawrence B. Marks, Céline Mascaux, Pierre P. Massion, Julien Mazieres, Annette McWilliams, Tetsuya Mitsudomi, Tony Mok, Daniel Morgensztern, Francoise Mornex, James L. Mulshine, Reginald F. Munden, Kristiaan Nackaerts, Shinji Nakamichi, Masayuki Noguchi, Krista Noonan, Silvia Novello, Anna K. Nowak, Kenneth J. O’Byrne, Nisha Ohri, Morihito Okada, Jamie S. Ostroff, Mamta Parikh, Elyse R. Park, Keunchil Park, Harvey I. Pass, Nicholas Pastis, Luis Paz-Ares, Nathan Pennell, Maurice Perol, Rathi N. Pillai, Pieter E. Postmus, Suresh S. Ramalingham, Sara Ramella, Ramón Rami-Porta, Martin Reck, Mary W. Redman, Niels Reinmuth, Umberto Ricardi, David Rice, Carole A. Ridge, William N. Rom, Kenneth E. Rosenzweig, Enrico Ruffini, Valerie W. Rusch, Ravi Salgia, Montse Sanchez-Cespedes, Anjali Saqi, Giorgio V. Scagliotti, Selma Schimmel, Ann G. Schwartz, Suresh Senan, Francis A. Shepherd, Jill M. Siegfried, Gerard A. Silvestri, George R. Simon, Egbert F. Smit, Stephen B. Solomon, Laura P. Stabile, Matthew A. Steliga, Thomas E. Stinchcombe, Nicholas S. Stollenwerk, Jong-Mu Sun, Anish Thomas, Ming-Sound Tsao, Jun-Chieh J. Tsay, Paul Van Houtte, Paul E. Van Schil, Nico van Zandwijk, J.F. Vansteenkiste, Marileila Varella-Garcia, Giulia Veronesi, Shalini K. Vinod, Everett E. Vokes, Heather Wakelee, Tonya C. Walser, Shun-ichi Watanabe, Walter Weder, Benjamin Wei, Ignacio I. Wistuba, James Chih-Hsin Yang, David F. Yankelevitz, Kazuhiro Yasufuku, Ken Y. Yoneda, Gérard Zalcman, Caicun Zhou, Yang Zhou, Daniel Zips
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76bdf7bb6ef73b271ecb1e7f91a917b6
https://doi.org/10.1016/b978-0-323-52357-8.01002-7
https://doi.org/10.1016/b978-0-323-52357-8.01002-7
Autor:
Eline H, van Roekel, Kar K, Cheng, Nicholas D, James, D Michael A, Wallace, Lucinda J, Billingham, Paul G, Murray, Richard T, Bryan, Maurice P, Zeegers
Publikováno v:
International journal of cancer. 133(2)
Smoking is a strong risk factor of bladder cancer (BC), but it is currently unclear whether smoking is also associated with severity of BC at diagnosis. We performed a large hospital-based case-comparison study, examining the relation between smoking